Apelin in Willis Ekbom Disease

Acibadem University

Status: Unknown

Conditions: Restless Legs Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT02264600

AWED-31014

Details and patient eligibility

About

The purpose of this study is to assess apelin level in patients with Willis-Ekbom Disease (WED) as known Restless Legs Syndrome (RLS). Cardiovascular complications of WED have been reported in recent studies. Increased oxidative stress is thought to play an important role in cardiovascular complications of WED patients. Apelin is a novel described antioxidant bioactive peptide. The investigators hypothesize that patients with WED have lower plasma apelin level than healthy subjects based on presence of oxidative stress of WED.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients diagnosed as RLS/WED according to International Classification of Sleep Disorders (ICSD-3) criteria
• Patients with idiopathic RLS/WED
• Moderate and severe RLS/WED according to International Restless Legs Syndrome Rating Scale
• Periodic Leg Movements Index above 5 in polysomnography record
• BMI below 25

Exclusion criteria

• Disorders which cause symptomatic RLS(Iron deficiency anemia, kidney failure, diabetes mellitus, pregnancy, Parkinson's disease, multiple sclerosis, neuropathy)
• Systemic diseases which cause possible oxidative stress status (cardiovascular diseases, obesity, diabetes mellitus, use of any medical drugs especially ACE inhibitors e.g.)
• Another sleep disorder